← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Health Research, Inc.
Rockville, MD
$77,046,781
Total funding
113
Grants
Funding over time
peak $10.6M · FY2008–25$20M$15M$10M$5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$60,290,921 · 100
CDC$9,108,003 · 6
ATSDR$3,700,019 · 2
NIH$2,368,266 · 3
NASA$1,181,673 · 1
DOE$397,899 · 1
By mechanism
—$61,870,493 · 102
U62$3,556,998 · 1
U61$3,305,831 · 1
N01$2,267,641 · 2
U58$2,160,000 · 1
U17$1,242,468 · 1
Investigators at Health Research, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
NOVEL IMMUNOTHERAPY FOR BRAIN-METASTATIC BREAST CANCER$6,420,739
· FY2019 · Defense Health Agency
VASCULAR-TARGETING ANTI-ANGIOGENIC THERAPY OF HUMAN BREAST CANCER$3,089,794
· FY2008 · Department of Defense
PS10-10138, EXPANDED HIV TESTING FOR DISPROPORTIONATELY AFFECTED POPULATIONS$2,867,386
U62 · FY2011 · PS
TARGETING STRESS PATHWAYS IN ESOPHAGUS CANCER TO BOOST ANTI-TUMOR IMMUNITY, PROMOTE RESPONSE TO THERAPY, AND PROLONG SURVIVAL$2,522,925
· FY2022 · Defense Health Agency
GENETIC AND EPIGENETIC PROSTATE CANCER-RELATED ALTERATIONS IN EARLY ONSET DISEASE IN AFRICAN AMERICAN MEN$2,465,451
· FY2017 · Department of the Army
ADVANCED CANCER GENOMICS INSTITUTE: GENETIC SIGNATURES AND THERAPEUTIC TARGETS IN CANCER PROGRESSION$1,747,000
· FY2011 · Department of the Army
TARGETING BRSK2 IN AGGRESSIVE BREAST CANCER BRAIN METASTASIS$1,710,727
· FY2024 · Defense Health Agency
ROLE OF ANDROGEN AXIS IN THE RACIAL DIFFERENCES OF PROSTATE CANCER MORTALITY$1,630,450
· FY2010 · Department of Defense
SLOW-CYCLING PROSTATE CANCER CELLS IN THERAPY RESISTANCE, DISEASE RELAPSE, AND METASTASIS$1,561,500
· FY2025 · Defense Health Agency
INHIBITING MDSC BIOGENESIS TO AUGMENT IMMUNOTHERAPY EFFICACY IN TRIPLE-NEGATIVE BREAST CANCER$1,301,250
· FY2025 · Defense Health Agency
PRESCRIPTION DRUG OVERDOSE PREVENTION IN NEW YORK STATE$1,242,468
U17 · FY2016 · CE
NOVEL MECHANISM-BASED PRECLINICAL CRPC MODELING IMPACTS PERSONALIZED TREATMENTS$1,200,000
· FY2016 · Department of the Army
BIOMONITORING OF SUSCEPTIBLE POPULATIONS IN NY ST GREAT LAKES$1,200,000
U61 · FY2012 · TS
BIOMONITORING OF SUSCEPTIBLE POPULATIONS IN NY ST GREAT LAKES$1,200,000
U61 · FY2011 · TS
PREVENTION OF METASTATIC BREAST CANCER WITH A TLR5 AGONIST$1,188,600
· FY2015 · Department of Defense
IDENTIFYING SOCIO-DEMOGRAPHIC CHARACTERISTICS THAT DETERMINE HEAT STRESS VULNERABILITY HAS BEEN DEEMED A PRIORITY HEALTH ACTION AREA BY THE CENTERS F$1,181,673
· FY2015 · National Aeronautics and Space Administration
LEVERAGING INFILTRATING MYELOID CELLS TO IMPROVE THERAPEUTIC RESPONSE TO BITE- SECRETING T CELLS IN OVARIAN CANCER$1,152,194
· FY2025 · Defense Health Agency
U.S. Based Collaboration in Emerging Viral Diseases$1,133,821
N01 · FY2009 · AI
U.S. Based Collaboration in Emerging Viral Diseases$1,133,820
N01 · FY2010 · AI
NEW YORK STATE VIRAL HEPATITIS SURVEILLANCE$1,120,591
U54 · FY2012 · PS